pdf   xlsx method abbreviations

mNSCLC - L1 - PDL1 positive, nivolumab plus ipilimumab , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.79 [0.65, 0.96]< 10%1 study (1/-)99.1 %NAnot evaluable crucial-
progression or deaths (PFS) 0.82 [0.69, 0.97]< 10%1 study (1/-)98.9 %NAnot evaluable important-
objective responses (ORR) 1.31 [0.97, 1.76]> 10%1 study (1/-)96.1 %NAnot evaluable non important-

safety endpoints 00

STRAE (any grade) 1.96 [1.36, 2.83]< 10%1 study (1/-)0.0 %NAnot evaluable non important-
STRAE (grade 3-4) 1.98 [1.32, 2.98]< 10%1 study (1/-)0.0 %NAnot evaluable non important-
TRAE (any grade) 0.66 [0.46, 0.94]< 10%1 study (1/-)98.8 %NAnot evaluable non important-
TRAE (grade 3-4) 0.96 [0.72, 1.29]< 10%1 study (1/-)60.1 %NAnot evaluable non important-
TRAE leading to death (grade 5) 0.99 [0.28, 3.45]< 10%1 study (1/-)50.7 %NAnot evaluable non important-
TRAE leading to discontinuation (any grade) 3.13 [1.95, 5.03]< 10%1 study (1/-)0.0 %NAnot evaluable non important-
TRAE leading to discontinuation (grade 3-4) 5.13 [2.63, 10.00]< 10%1 study (1/-)0.0 %NAnot evaluable non important-

TRAE (grade 3-4) endpoints 00

Anaemia TRAE (grade 3-4) 0.11 [0.04, 0.28]< 10%1 study (1/-)100.0 %NAnot evaluable non important-
Asthenia TRAE (grade 3-4) 1.24 [0.33, 4.65]< 10%1 study (1/-)37.5 %NAnot evaluable non important-
Constipation TRAE (grade 3-4) 0.99 [0.02, 50.01]< 10%1 study (1/-)50.2 %NAnot evaluable non important-
Decreased appetite TRAE (grade 3-4) 0.99 [0.25, 3.99]< 10%1 study (1/-)50.6 %NAnot evaluable non important-
Diarrhoea TRAE (grade 3-4) 3.00 [0.60, 14.96]< 10%1 study (1/-)9.1 %NAnot evaluable non important-
Fatigue TRAE (grade 3-4) 2.00 [0.60, 6.70]< 10%1 study (1/-)13.1 %NAnot evaluable non important-
Nausea TRAE (grade 3-4) 0.28 [0.06, 1.35]< 10%1 study (1/-)94.3 %NAnot evaluable non important-
Neutropenia TRAE (grade 3-4) 0.01 [0.00, 0.23]< 10%1 study (1/-)99.9 %NAnot evaluable non important-
Pruritus TRAE (grade 3-4) 3.97 [0.18, 88.42]< 10%1 study (1/-)19.5 %NAnot evaluable non important-
Rash TRAE (grade 3-4) 18.21 [1.05, 315.26]< 10%1 study (1/-)2.4 %NAnot evaluable non important-
Vomiting TRAE (grade 3-4) 0.10 [0.01, 0.76]< 10%1 study (1/-)98.6 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons